URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Michael Grey Biography and Net Worth

Director of BioMarin Pharmaceutical

Michael G. Grey is an entrepreneur and businessperson who founded Mirum Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc. and Lumena Pharmaceuticals, Inc. and who has been at the head of 16 different companies. Presently, he holds the position of Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Chairman at Mirum Pharmaceuticals, Inc., Chairman at Plexium, Inc., Venture partner at Pappas Capital LLC and Executive Chairman at Amplyx Pharmaceuticals, Inc. Michael G. Grey is also on the board of Biothera, Inc., Horizon Therapeutics Plc and San Diego Venture Group.

In the past he occupied the position of Director at Curzion Pharmaceuticals, Inc., President & Chief Operating Officer for Ansan, Inc., Non-Executive Chairman of IDM Pharma, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman of Ziarco Group Ltd., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer for Ansan Pharmaceuticals, Inc., President & Chief Executive Officer of Auspex Pharmaceuticals, Inc., President at Biochem Therapeutic, Inc., Vice President-Corporate Development at Glaxo, Inc. and Vice President-Corporate Development for Glaxo Holdings Plc.

Michael G. Grey received an undergraduate degree from The University of Nottingham.

What is Michael G. Grey's net worth?: The estimated net worth of Michael G. Grey is at least $984,900.00 as of April 12th, 2021. Mr. Grey owns 15,000 shares of BioMarin Pharmaceutical stock worth more than $984,900 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Grey may own. Learn More about Michael G. Grey's net worth.
How do I contact Michael G. Grey?: The corporate mailing address for Mr. Grey and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on Michael G. Grey's contact information.
Has Michael G. Grey been buying or selling shares of BioMarin Pharmaceutical?: Michael G. Grey has not been actively trading shares of BioMarin Pharmaceutical during the last quarter. Most recently, Michael G. Grey sold 5,000 shares of the business's stock in a transaction on Friday, March 5th. The shares were sold at an average price of $76.28, for a transaction totalling $381,400.00. Following the completion of the sale, the director now directly owns 47,840 shares of the company's stock, valued at $3,649,235.20. Learn More on Michael G. Grey's trading history.
Who are BioMarin Pharmaceutical's active insiders?: BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.
Are insiders buying or selling shares of BioMarin Pharmaceutical?: In the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 196,207 shares worth more than $16,544,419.92. The most recent insider tranaction occured on November, 12th when EVP Charles Greg Guyer sold 5,278 shares worth more than $350,300.86. Insiders at BioMarin Pharmaceutical own 1.9% of the company. Learn More about insider trades at BioMarin Pharmaceutical.
Information on this page was last updated on 11/12/2024.

Michael G. Grey Insider Trading History at BioMarin Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2021	Sell	5,000	$76.28	$381,400.00	47,840
8/3/2020	Sell	2,500	$120.35	$300,875.00	45,340
2/22/2016	Sell	7,500	$80.00	$600,000.00	33,750

Michael G. Grey Buying and Selling Activity at BioMarin Pharmaceutical

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $65.66

$64.07

$66.27

50 Day Range

MA: $66.58

$61.93

$70.53

2 Week Range

Now: $65.66

$61.15

$99.25

Volume

3,974,318 shs

Average Volume

1,808,870 shs

Market Capitalization

$12.51 billion

P/E Ratio

39.32

Dividend Yield

N/A

Beta

0.29

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.